Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Arschang Valipour, Sergey Avdeev, Adam Barczyk, Valentina Bayer, Zvi Fridlender, Mariela Georgieva, Ondřej Kudela, Alexey Medvedchikov, Ramona Miron, Maria Sanzharovskaya, Virginija Šileikienė, Jurij Šorli, Marc Spielmanns & Zsuzsanna Szalai. (2021) Therapeutic Success of Tiotropium/Olodaterol, Measured Using the Clinical COPD Questionnaire (CCQ), in Routine Clinical Practice: A Multinational Non-Interventional Study. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 615-628.
Read now
Read now
Tanja Fens, Guiling Zhou, Maarten J. Postma, Eugène P. van Puijenbroek & Job F.M. van Boven. (2021) Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?. Expert Opinion on Pharmacotherapy 22:7, pages 923-935.
Read now
Read now
Marc Miravitlles, Alicia Marín, Alicia Huerta, David Carcedo, Alba Villacampa & Jaume Puig-Junoy. (2020) Estimation of the Clinical and Economic Impact of an Improvement in Adherence Based on the Use of Once-Daily Single-Inhaler Triple Therapy in Patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 1643-1654.
Read now
Read now
Melanie Schroeder, Nicole Benjamin, Laura Atienza, Chandroday Biswas, Alan Martin, John D Whalen, José Luis Izquierdo Alonso, Juan Antonio Riesco Miranda, Juan José Soler-Cataluña, Alicia Huerta & Afisi S Ismaila. (2020) Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 1621-1632.
Read now
Read now
Mafalda Ramos, Mark Lamotte, Laetitia Gerlier, Per Svangren, Anna Miquel-Cases & John Haughney. (2019) Cost-effectiveness of physical activity in the management of COPD patients in the UK. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 227-239.
Read now
Read now
Mario Malerba, Alessandro Radaeli, Paolo Montuschi & Jaymin B. Morjaria. (2016) Vilanterol trifenatate for the treatment of COPD. Expert Review of Respiratory Medicine 10:7, pages 719-731.
Read now
Read now
Job FM van Boven, Janwillem WH Kocks & Maarten J Postma. (2016) Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium–olodaterol for patients with COPD in the Netherlands. International Journal of Chronic Obstructive Pulmonary Disease 11, pages 2191-2201.
Read now
Read now
Articles from other publishers (11)
Yinhua Gong, Chen Lin, Yifeng Jin & Rong Chen. (2022) The Efficacy and Cost-Effectiveness of Umeclidinium/Vilanterol versus Tiotropium in Symptomatic Patients with Chronic Obstructive Pulmonary Disease. Canadian Respiratory Journal 2022, pages 1-12.
Crossref
Crossref
Jieun Kang, Jae Seung Lee, Sei Won Lee, Jung Bok Lee & Yeon-Mok Oh. (2021) Dual versus monotherapy with bronchodilators in GOLD group B COPD patients according to baseline FEV1 level: a patient-level pooled analysis of phase-3 randomized clinical trials. Respiratory Research 22:1.
Crossref
Crossref
David Slade, Riju Ray, Chad Moretz, Guillaume Germain, François Laliberté, Qin Shen, Mei Sheng Duh, Malena Mahendran & Beth Hahn. (2021) Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study. BMC Pulmonary Medicine 21:1.
Crossref
Crossref
Maren E. Shipe, Amelia W. Maiga, Stephen A. Deppen, Diane N. Haddad, Erin A. Gillaspie, Fabien Maldonado, Benjamin D. Kozower & Eric L. Grogan. (2021) Cost-Effectiveness Analysis of Fibrinolysis vs Thoracoscopic Decortication for Early Empyema. The Annals of Thoracic Surgery 112:5, pages 1632-1638.
Crossref
Crossref
Wijdan H. Ramadan, Sarah Al Masri & John Rizk. (2019) Fixed‐dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review. The Clinical Respiratory Journal 13:11, pages 663-673.
Crossref
Crossref
Ami R. Buikema, Lee Brekke, Amy Anderson, Eleena Koep, Damon Van Voorhis, Lucie Sharpsten, Beth Hahn, Riju Ray & Richard H. Stanford. (2018) The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models. Multidisciplinary Respiratory Medicine 13:1.
Crossref
Crossref
Dhvani Shah, Maurice Driessen, Nancy Risebrough, Timothy Baker, Ian Naya, Andrew Briggs & Afisi S. Ismaila. (2018) Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective. Cost Effectiveness and Resource Allocation 16:1.
Crossref
Crossref
M. T. Driessen, J. Whalen, B. Seewoodharry Buguth, L. A. Vallejo-Aparicio, I. P. Naya, Y. Asukai, B. Alcázar-Navarrete, M. Miravitlles, F. García-Río & N. A. Risebrough. (2018) Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective. Respiratory Research 19:1.
Crossref
Crossref
Margarita Capel, María Mareque, Carlos José Álvarez, Leandro Lindner & Itziar Oyagüez. (2018) Cost-Effectiveness of Fixed-Dose Combinations Therapies for Chronic Obstructive Pulmonary Disease Treatment. Clinical Drug Investigation 38:7, pages 611-620.
Crossref
Crossref
Leif Bjermer, Job F. M. van Boven, Madlaina Costa-Scharplatz, Dorothy L. Keininger, Florian S. Gutzwiller, Karin Lisspers, Ronan Mahon, Petter Olsson & Nicolas Roche. (2017) Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population. Respiratory Research 18:1.
Crossref
Crossref
M. Reza Maleki-Yazdi, Mathieu Molimard, Dorothy L. Keininger, Jean-Bernard Gruenberger, Joao Carrasco, Claudia Pitotti, Elsa Sauvage, Sara Chehab & David Price. (2016) Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal. Applied Health Economics and Health Policy 14:5, pages 579-594.
Crossref
Crossref